These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 20227723)

  • 1. B-type natriuretic peptide predicts responses to indomethacin in premature neonates with patent ductus arteriosus.
    Hsu JH; Yang SN; Chen HL; Tseng HI; Dai ZK; Wu JR
    J Pediatr; 2010 Jul; 157(1):79-84. PubMed ID: 20227723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus.
    Attridge JT; Kaufman DA; Lim DS
    Arch Dis Child Fetal Neonatal Ed; 2009 May; 94(3):F178-82. PubMed ID: 18981033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants.
    Choi BM; Lee KH; Eun BL; Yoo KH; Hong YS; Son CS; Lee JW
    Pediatrics; 2005 Mar; 115(3):e255-61. PubMed ID: 15687418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Point-of-care testing for B-type natriuretic peptide in premature neonates with patent ductus arteriosus.
    Kalra VK; DeBari VA; Zauk A; Kataria P; Myridakis D; Kiblawi F
    Ann Clin Lab Sci; 2011; 41(2):131-7. PubMed ID: 21844570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation analysis between echocardiographic flow pattern and N-terminal-pro-brain natriuretic peptide for early targeted treatment of patent ductus arteriosus.
    Occhipinti F; De Carolis MP; De Rosa G; Bersani I; Lacerenza S; Cota F; Rubortone SA; Romagnoli C
    J Matern Fetal Neonatal Med; 2014 Nov; 27(17):1800-4. PubMed ID: 24397409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates.
    Flynn PA; da Graca RL; Auld PA; Nesin M; Kleinman CS
    J Pediatr; 2005 Jul; 147(1):38-42. PubMed ID: 16027692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Therapeutic Response to Cyclooxygenase Inhibitors in Preterm Infants with Patent Ductus Arteriosus.
    Hu Y; Jin H; Jiang Y; Du J
    Pediatr Cardiol; 2018 Apr; 39(4):647-652. PubMed ID: 29468349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates.
    Sanjeev S; Pettersen M; Lua J; Thomas R; Shankaran S; L'Ecuyer T
    J Perinatol; 2005 Nov; 25(11):709-13. PubMed ID: 16222347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-type natriuretic peptide to predict ductus intervention in infants <28 weeks.
    Czernik C; Lemmer J; Metze B; Koehne PS; Mueller C; Obladen M
    Pediatr Res; 2008 Sep; 64(3):286-90. PubMed ID: 18414139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indomethacin tocolysis increases postnatal patent ductus arteriosus severity.
    Hammerman C; Glaser J; Kaplan M; Schimmel MS; Ferber B; Eidelman AI
    Pediatrics; 1998 Nov; 102(5):E56. PubMed ID: 9794986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-type and N-terminal pro-B-type natriuretic peptides are equally useful in assessing patent ductus arteriosus in very preterm infants.
    König K; Guy KJ; Drew SM; Barfield CP
    Acta Paediatr; 2015 Apr; 104(4):e139-42. PubMed ID: 25488470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two neonatal indomethacin protocols: efficacy and outcome for patent ductus arteriosus closure.
    Rosito G; Sum K; Chorne N
    J Clin Pharm Ther; 2010 Oct; 35(5):589-92. PubMed ID: 20831682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent Doppler flow predicts lack of response to multiple courses of indomethacin in premature infants with recurrent patent ductus arteriosus.
    Keller RL; Clyman RI
    Pediatrics; 2003 Sep; 112(3 Pt 1):583-7. PubMed ID: 12949288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-terminal-pro-brain natriuretic peptide: a guide for early targeted indomethacin therapy for patent ductus arteriosus in preterm Infants.
    Nuntnarumit P; Chongkongkiat P; Khositseth A
    Acta Paediatr; 2011 Sep; 100(9):1217-21. PubMed ID: 21457304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-type natriuretic peptide for assessment of haemodynamically significant patent ductus arteriosus in premature infants.
    Mine K; Ohashi A; Tsuji S; Nakashima J; Hirabayashi M; Kaneko K
    Acta Paediatr; 2013 Aug; 102(8):e347-52. PubMed ID: 23611593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duration of indomethacin treatment of the preterm patent ductus arteriosus as directed by echocardiography.
    Carmo KB; Evans N; Paradisis M
    J Pediatr; 2009 Dec; 155(6):819-822.e1. PubMed ID: 19643435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What happens when the patent ductus arteriosus is treated less aggressively in very low birth weight infants?
    Kaempf JW; Wu YX; Kaempf AJ; Kaempf AM; Wang L; Grunkemeier G
    J Perinatol; 2012 May; 32(5):344-8. PubMed ID: 21818064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of indomethacin on closure of ductus arteriosus in very-low-birthweight neonates.
    Godambe S; Newby B; Shah V; Shah PS
    Acta Paediatr; 2006 Nov; 95(11):1389-93. PubMed ID: 17062465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of PDA Treatment in Preterm Neonates Who Had Received Prophylactic Indomethacin.
    Louis D; ElSayed YN; Ojah C; Alvaro R; Shah PS; Dunn M;
    Am J Perinatol; 2018 Apr; 35(5):509-514. PubMed ID: 29183097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of failed closure of patent ductus arteriosus with indomethacin.
    Boo NY; Mohd-Amin I; Bilkis AA; Yong-Junina F
    Singapore Med J; 2006 Sep; 47(9):763-8. PubMed ID: 16924357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.